Detalhe da pesquisa
1.
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.
Ann Hematol
; 2024 Apr 03.
Artigo
Inglês
| MEDLINE | ID: mdl-38568260
2.
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
Haematologica
; 104(11): 2249-2257, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30890600
3.
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Blood Adv
; 6(17): 5132-5145, 2022 09 13.
Artigo
Inglês
| MEDLINE | ID: mdl-35728048
4.
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
PLoS One
; 16(9): e0257353, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34506616
5.
Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid.
Expert Rev Hematol
; 14(1): 1-5, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33280467